Feature
Jade Corporate Presentation
Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases.
Our lead candidate, JADE101, targets the anti-APRIL (A Proliferation-Inducing Ligand) pathway for the treatment of immunoglobin A nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. JADE101 aims to reduce harmful IgA antibodies, lower proteinuria (a key marker of kidney damage), and preserve long-term kidney function. A first-in-human clinical trial is expected to begin in the second half of 2025, with interim biomarker-rich data anticipated in early 2026.
Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. See our pipeline to learn more.
Events &
Presenations
March 11, 2025 - March 12, 2025
Jefferies Biotech on the Beach Summit
March 3, 2025 - March 5, 2025
TD Cowen’s 45th Annual Health Care Conference
November 20, 2024 at 12:00 pm (GMT (U.K.))
2024 Jefferies London Healthcare Conference
November 18, 2024 at 4:45 pm (ET)
Stifel 2024 Healthcare Conference
October 31, 2024 at 8:30 am (EDT)
Jade Biosciences Conference Call